Clinical Trial Update: Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer

View source ↗

Summary

Daiichi Sankyo offers a medical access program for Ifinatamab Deruxtecan in third-line or later extensive-stage small cell lung cancer, with the program status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Ifinatamab Deruxtecan (Ifinatamab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: SCLC, Extensive-stage Small Cell Lung Cancer | Status: AVAILABLE